The Primacy of Public Health Considerations in Defining Poor Quality Medicines
PLoS Medicine 8(12): e1001139-e1001139
Article 2011 English
Authors
PN
Paul N. Newton
AA
Abdinasir A Amin
CB
Chris Bird
Abstract
1 min read
Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.
Paul N. Newton, Sue J. Lee, Catherine Goodman, Facundo M. Fernández, Shunmay Yeung, Souly Phanouvong, Harparkash Kaur, Abdinasir A Amin, C. W. M. Whitty, Gilbert Kokwaro, Niklas Lindegårdh, Patrick Lukulay, Lisa J. White, Nicholas Day, Michael D. Green, Sir Nicholas White
Paul N. Newton, Patricia Tabernero, Prabha Dwivedi, María J. Culzoni, Marı́a Eugenia Monge, Isabel Swamidoss, Dallas C. Mildenhall, Michael D. Green, Richard W. O. Jähnke, Miguel dos Santos de Oliveira, Julia Simao, Sir Nicholas White, Facundo M. Fernández
Paul N. Newton, David Schellenberg, Elizabeth A. Ashley, Raffaella Ravinetto, Michael D. Green, Feiko O. ter Kuile, Patricia Tabernero, Sir Nicholas White, Philippe J. Guérin
Hans‐Jürgen Rumpf, Sophia Achab, Joël Billieux, Henrietta Bowden‐Jones, Natacha Carragher, Zsolt Demetrovics, Susumu Higuchi, Daniel L. King, Karl Mann, Marc N. Potenza, John B. Saunders, Max Abbott, Atul Ambekar, Osman Tolga Arıcak, Sawitri Assanangkornchai, Norharlina Bahar, Guilherme Borges, Matthias Brand, Elda M. L. Chan, Thomas Chung, Jeff Derevensky, Ahmad El Kashef, Michael Farrell, Naomi Fineberg,
Discussion(0)
No comments yet. Be the first to comment.